{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:53:37Z","timestamp":1791305617568,"version":"4.3.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["#13493"],"award-info":[{"award-number":["#13493"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leukemiefonds"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"DOI":"10.1038\/s41409-026-03063-0","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:10:17Z","timestamp":1791303017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peri-transplant ruxolitinib in myelofibrosis patients undergoing \u03b1\u03b2TCR and CD19-depleted stem cell transplantation"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0797-4050","authenticated-orcid":false,"given":"Anniek","family":"Stuut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flores","family":"Weverling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Verheij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Brinkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaartje","family":"Nijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5017-8415","authenticated-orcid":false,"given":"Pleun","family":"Schonewille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christien","family":"Oudbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2276-8806","authenticated-orcid":false,"given":"Anna","family":"van Rhenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte","family":"van der Wagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9835-3223","authenticated-orcid":false,"given":"Laura","family":"Daenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinier","family":"Raymakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper","family":"Westinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5353-1740","authenticated-orcid":false,"given":"Tim","family":"Hutten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4089-980X","authenticated-orcid":false,"given":"Lisette","family":"van de Corput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Drylewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3914-7806","authenticated-orcid":false,"given":"Jurgen","family":"Kuball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7470-2994","authenticated-orcid":false,"given":"Moniek","family":"de Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"3063_CR1","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1038\/s41409-021-01305-x","volume":"56","author":"D McLornan","year":"2021","unstructured":"McLornan D, Eikema DJ, Czerw T, Kroger N, Koster L, Reinhardt HC, et al. Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis. Bone Marrow Transpl. 2021;56:2160\u201372.","journal-title":"Bone Marrow Transpl"},{"key":"3063_CR2","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787\u201398.","journal-title":"N Engl J Med"},{"key":"3063_CR3","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","volume":"382","author":"R Zeiser","year":"2020","unstructured":"Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382:1800\u201310.","journal-title":"N Engl J Med"},{"key":"3063_CR4","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.bbmt.2018.05.023","volume":"24","author":"N Kroger","year":"2018","unstructured":"Kroger N, Shahnaz Syed Abd Kadir S, Zabelina T, Badbaran A, Christopeit M, Ayuk F, et al. Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation. Biol Blood Marrow Transpl. 2018;24:2152\u20136.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3063_CR5","first-page":"1","volume":"2","author":"GS Hobbs","year":"2025","unstructured":"Hobbs GS, Haesook TK, Hao R, Schroeder MA, Tamari R, Wall S, et al. Phase II study of peri- and post-transplant ruxolitinib for patients with myelofibrosis receiving allogeneic hematopoietic cell transplantation. JCO Oncol Adv. 2025;2:1\u201310.","journal-title":"JCO Oncol Adv"},{"key":"3063_CR6","doi-asserted-by":"crossref","unstructured":"Stuut AHG, Nijssen C, van der Wagen L, van Rhenen A, Daenen LGM, Janssen A, et al. Improved GVHD-free and relapse-free survival after ex vivo \u03b1\u03b2TCR and CD19 depleted allogeneic HSCT compared to T cell replete HSCT. Bone Marrow Transplant. 2025;60:673\u201381.","DOI":"10.1038\/s41409-025-02538-w"},{"key":"3063_CR7","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/s41375-021-01449-1","volume":"36","author":"S Kunte","year":"2022","unstructured":"Kunte S, Rybicki L, Viswabandya A, Tamari R, Bashey A, Keyzner A, et al. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia. 2022;36:856\u201364.","journal-title":"Leukemia"},{"key":"3063_CR8","doi-asserted-by":"crossref","unstructured":"Chiusolo P, Bacigalupo A, Salit R, Schroeder T, Finazzi MC, Gurnari C, et al. PTCy or ATG for Matched Transplantation in Myelofibrosis. Am J Hematol. 2026;101:1192\u20135.","DOI":"10.1002\/ajh.70244"},{"key":"3063_CR9","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41409-024-02220-7","volume":"59","author":"S Oechsler","year":"2024","unstructured":"Oechsler S, Gagelmann N, Wolschke C, Janson D, Badbaran A, Klyuchnikov E, et al. Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2024;59:550\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"3063_CR10","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1038\/s41375-025-02754-9","volume":"39","author":"RB Salit","year":"2025","unstructured":"Salit RB, Hexner EO, Gagelmann N, Kroger N, McLornan DP, Jain T, et al. Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus. Leukemia. 2025;39:2862\u20135.","journal-title":"Leukemia"},{"key":"3063_CR11","doi-asserted-by":"publisher","first-page":"e921","DOI":"10.1097\/HS9.0000000000000921","volume":"7","author":"N Gagelmann","year":"2023","unstructured":"Gagelmann N, Wolschke C, Badbaran A, Janson D, Berger C, Klyuchnikov E, et al. Donor lymphocyte infusion and molecular monitoring for relapsed myelofibrosis after hematopoietic cell transplantation. Hemasphere. 2023;7:e921.","journal-title":"Hemasphere"},{"key":"3063_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa2408941","volume":"392","author":"N Gagelmann","year":"2025","unstructured":"Gagelmann N, Quarder M, Badbaran A, Rathje K, Janson D, Luck C, et al. Clearance of driver mutations after transplantation for myelofibrosis. N Engl J Med. 2025;392:150\u201360.","journal-title":"N Engl J Med"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03063-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03063-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03063-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:10:20Z","timestamp":1791303020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03063-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":12,"alternative-id":["3063"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-03063-0","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"5 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JK is inventor on multiple patents dealing with gdTCRs, ligands, isolation strategies of engineered immune cells. JK is cofounder and shareholder of Gadeta (\n                      \n                      ). JK received research, advisor and clinical study support from Miltenyi Biotech. JK received further research support from Novartis and Gadeta.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All eligible patients provided written informed consent before transplantation. The study was approved by the Medisch Ethische Toetsingscommissie Utrecht (METC Utrecht, METC nr 21-322), in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}]}}